BridgeMD
Open-label, prospective study evaluating the efficacy and safety of Tirbanibulin 1% (Klisyri®) in the treatment of superficial basal cell carcinoma
EU CTIS ID: 2023-505971-66-00
What this study is testing
Evaluate the efficacy of Tirbanibulin (Klisyri®) in the treatment of BCCs.
- Phase II and Phase III (Integrated)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Male and female patients over 18 years of age.
- Patients with one or more primary, superficial BCCs of the trunk or limbs confirmed by LC-OCT.
- Primitive BCC, long axis less than or equal to 15 mm.
- Patient affiliated to a Social Security scheme.
- Patient likely to understand study instructions.
- Signed informed consent. If necessary, a legal representative can sign the consent form.
You likely can't join if
- BCC scalp and face
- Recurrent BCC
- Non-superficial BCC
- BCC diameter > 15 mm
- Patient allergic to Tirbanibulin to an excipient of the finished product
- Treatment with cryotherapy, imiquimod, PDT, or radiotherapy in the treatment area within 6 months prior to the first visit
See the full eligibility criteria
- Male and female patients over 18 years of age.
- Patients with one or more primary, superficial BCCs of the trunk or limbs confirmed by LC-OCT.
- Primitive BCC, long axis less than or equal to 15 mm.
- Patient affiliated to a Social Security scheme.
- Patient likely to understand study instructions.
- Signed informed consent. If necessary, a legal representative can sign the consent form.
- BCC scalp and face
- Recurrent BCC
- Non-superficial BCC
- BCC diameter > 15 mm
- Patient allergic to Tirbanibulin to an excipient of the finished product
- Treatment with cryotherapy, imiquimod, PDT, or radiotherapy in the treatment area within 6 months prior to the first visit
- Pregnant or breast-feeding women (a urine pregnancy test will be performed)
- Current participation or less than 30 days' participation in a clinical drug trial
- Any medical or psychiatric condition that could prevent the proper understanding and conduct of treatment and study (adults under guardianship)
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years, 65+ years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.